H. Lundbeck, successful completion of rasagiline phase III clinical program

H. Lundbeck A/S and Teva Pharmaceutical Industries, Ltd. are pleased to announce the successful completion of two phase III clinical trials of rasagiline in patients with advanced Parkinson's disease.